Skip to main content
Takeda's Adcetris gains NICE recommendation for Hodgkin lymphoma

The National Institute for Health and Care Excellence has recommended use of Takeda's Adcetris, or brentuximab vedotin, as a treatment for adult patients with CD30-positive Hodgkin lymphoma who have relapsed or refractory disease following autologous stem cell transplant. Funding via the Cancer Drugs Fund was also backed by NICE for adult patients with CD30+ve R/R Hodgkin lymphoma who have had at least two previous therapies and for whom ASCT or multiagent chemotherapy are not treatment options.

Full Story: